Scienture Holdings (SCNX) Q2 2026 earnings summary

Executive summary

• Achieved 510% sequential revenue growth in Q2 2026, reaching $343,639, driven by commercial expansion, new product launches, and the launch of ARBLI™ and REZENOPY™.

• Focus shifted to specialty pharmaceuticals with divestiture of legacy subsidiaries and acquisition of Scienture, LLC in July 2024.

• Three additional candidates remain in the pipeline targeting CNS and CVS diseases.

• Revenue growth concentrated among three major U.S. wholesale distributors.

Financial highlights

• Q2 2026 revenue was $343,639, up from $0 in Q2 2025; first-half 2026 revenue reached $399,964, up from $10,258 year-over-year.

• Q2 2026 gross profit was $335,779, with a gross margin of 97.7%.

• Q2 2026 net loss was $2,822,371, a 58% improvement from Q2 2025; six-month net loss was $6,224,635, down 36% year-over-year.

• Q2 2026 operating expenses decreased 41% year-over-year to $3.0 million; adjusted EBITDA for Q2 2026 was $(2,134,705).

• Cash, cash equivalents, and restricted cash totaled $11.2 million as of June 30, 2026.

Outlook and guidance

• Management expects continued revenue growth from ARBLI™ and REZENOPY™, with revenue acceleration into 2027.

• Operating leverage and disciplined expense management are expected to support profitability in 2027.

• Existing cash, product revenues, and planned financing are expected to fund operations for at least 12 months.

• Ongoing focus on advancing pipeline candidates and strategic business development.